Principal Scientist, Drug Substance Process Development at Abata Therapeutics

Burlington, Massachusetts, United States

Abata Therapeutics Logo
Not SpecifiedCompensation
Senior (5 to 8 years), Expert & Leadership (9+ years)Experience Level
Full TimeJob Type
UnknownVisa
Biotechnology, PharmaceuticalsIndustries

Requirements

  • Degree in Synthetic Organic Chemistry or related discipline with relevant industry experience (PhD: 5+ yrs, MS: 10+ yrs, BS: 12+ yrs)
  • Proven track record of managing CRO/CDMO relationships and delivering on CMC milestones
  • Strong understanding of GMP manufacturing and ICH regulatory requirements
  • Excellent written and verbal communication skills
  • Demonstrated ability to manage multiple projects and priorities effectively
  • High attention to detail and commitment to scientific rigor
  • Strong team player with a collaborative mindset and ability to work effectively across disciplines
  • Ability to self-motivate and work independently
  • Flexibility to attend weekly calls, especially with CDMOs in different time-zones
  • Ability to travel up to 25% of time
  • Preferred Experience
  • Prior involvement in late-stage development and tech transfer activities
  • Familiarity with QbD principles and risk-based development approaches

Responsibilities

  • Lead the phase-appropriate development, scale-up, and optimization of cost-effective synthetic routes for small molecule drug substances intended for CNS therapeutics
  • Oversee and manage relationships with CROs and CDMOs to ensure timely and quality delivery of drug substance materials and data
  • Author and review CMC sections of regulatory filings including INDs, IMPDs, and NDAs. Ensure alignment with global regulatory expectations
  • Lead investigations and resolution of quality events (e.g., deviations, OOS, OOT). Collaborate with Quality Assurance to ensure compliance with GMP standards
  • Work closely with Analytical Development, Formulation, Regulatory Affairs, Drug Discovery, and Clinical Supply teams to support integrated development strategies
  • Drive timelines, budgets, and deliverables across multiple projects. Communicate progress and risks effectively to stakeholders
  • Prepare and critically review technical reports, protocols, and development summaries with high attention to detail
  • Foster a collaborative team environment and contribute to cross-functional problem solving and decision making
  • Promote technical excellence through mentoring, peer review, and continuous improvement initiatives

Skills

synthetic organic chemistry
process development
scale-up
CRO management
CDMO management
CMC
regulatory filings
IND
IMPD
NDA
GMP compliance
project management
quality investigations

Abata Therapeutics

Develops therapies for autoimmune diseases

About Abata Therapeutics

Abata Therapeutics develops therapies for autoimmune diseases, focusing on type 1 diabetes. Their main product, ABA 201, is a Treg cell therapy aimed at patients with some remaining beta cell function. This therapy works by utilizing regulatory T cells to improve patient outcomes. Unlike many competitors, Abata targets a specific niche within the autoimmune disease market and collaborates with partners like ElevateBio for process development and manufacturing. The company's goal is to transform treatment options for autoimmune diseases through advanced research and development.

Cambridge, MassachusettsHeadquarters
2021Year Founded
$184.8MTotal Funding
EARLY_VCCompany Stage
BiotechnologyIndustries
11-50Employees

Risks

Intensifying competition from companies like Sangamo Therapeutics may impact Abata's market share.
Stringent FDA scrutiny on manufacturing could delay Abata's clinical trials.
Rising clinical trial costs pose financial risks to Abata's pipeline progression.

Differentiation

Abata focuses on Treg cell therapies for autoimmune diseases like MS and diabetes.
Their lead product, ABA 201, targets type 1 diabetes with remaining beta cell function.
Abata's strategic partnership with ElevateBio enhances their manufacturing capabilities.

Upsides

Recent investment from Bristol Myers Squibb boosts Abata's Treg therapy pipeline development.
FDA's accelerated approval pathways may expedite Abata's clinical trials.
Growing autoimmune disease prevalence increases demand for Abata's innovative treatments.

Land your dream remote job 3x faster with AI